Form DEFA14A GYRE THERAPEUTICS, INC.
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
|
Filed by the Registrant
|
|
|
☒
|
|
Filed by a Party other than the Registrant
|
|
|
☐
|
Check the appropriate box:
|
☐
|
Preliminary Proxy Statement
|
||||
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
||||
|
☐
|
Definitive Proxy Statement
|
||||
|
☒
|
Definitive Additional Materials
|
||||
|
☐
|
Soliciting Material under §240.14a-12
|
||||
Gyre Therapeutics, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
|
☒
|
No fee required.
|
||
|
☐
|
Fee paid previously with preliminary materials.
|
||
|
☐
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Simply Solventless Provides Update on Filing of 2025 Annual Financial Statements and Related Management's Discussion and Analysis and Management Cease Trade Order
- Zentro Announces Expansion of Digital Asset Services Focused on Liquidity and Payment Solutions in the United Arab Emirates
- Can an AI Tool Replace a Real Estate Agent in Westchester County?
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
